Your browser doesn't support javascript.
loading
Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss.
Castelo-Branco, C; Cancelo Hidalgo, M J; Palacios, S; Ciria-Recasens, M; Fernández-Pareja, A; Carbonell-Abella, C; Manasanch, J; Haya-Palazuelos, J.
Affiliation
  • Castelo-Branco C; Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic-Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Cancelo Hidalgo MJ; Obstetrics and Gynaecology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
  • Palacios S; Universidad de Alcalá, Alcalá de Henares (Madrid), Spain.
  • Ciria-Recasens M; Director of Palacios Institute of Woman's Health, Madrid, Spain.
  • Fernández-Pareja A; Rheumatology Department, Parc de Salud Mar, Hospital Universitari del Mar, Barcelona, Spain.
  • Carbonell-Abella C; CMSc, Departamento I de Prevención y Promoción de la Salud Hortaleza, Madrid, Spain.
  • Manasanch J; Primary Care Health Centre Vía Roma, Universitat de Barcelona, Barcelona, Spain.
  • Haya-Palazuelos J; Pierre Fabre Ibérica, Dep. Médico-Científico, Barcelona, Spain.
Climacteric ; 23(3): 252-258, 2020 06.
Article in En | MEDLINE | ID: mdl-31747785
Objective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice.Methods: The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) T-score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded.Results: In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm2). BMD in the CC arm decreased -3.1% (mean [SD] - 0.03 [0.11] g/cm2). Between-group differences were statistically significant (p < 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p = 0.001), affecting primarily the gastrointestinal system.Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Calcium Carbonate / Osteoporosis, Postmenopausal / Durapatite Type of study: Clinical_trials / Observational_studies Limits: Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Climacteric Journal subject: GINECOLOGIA Year: 2020 Document type: Article Affiliation country: España Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Calcium Carbonate / Osteoporosis, Postmenopausal / Durapatite Type of study: Clinical_trials / Observational_studies Limits: Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Climacteric Journal subject: GINECOLOGIA Year: 2020 Document type: Article Affiliation country: España Country of publication: Reino Unido